Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROMETHEUS: Autologous MSCs for Chronic Ischemic LV Dysfunction
NCT00587990Phase 2Terminated
- Start
- Nov 2007
- Primary completion
- Jun 2011
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of autologous mesenchymal stem cells in ischemic cardiomyopathy (ICM) (3 arms). Primary endpoint: Number of Patients With Serious Adverse Events at 12 months. Started Nov 2007; status: terminated.
02
Drugs
autologous mesenchymal stem cells
03
Conditions
ischemic cardiomyopathy (ICM)
Beyond the preview
Go deeper on NCT00587990.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00587990.